| Literature DB >> 33233645 |
Andrzej Kubiak1, Tomasz Zieliński1, Joanna Pabijan1, Małgorzata Lekka1.
Abstract
Increasing attention is devoted to the use of nanomechanics as a marker of various pathologies. Atomic force microscopy (AFM) is one of the techniques that could be applied to quantify the nanomechanical properties of living cells with a high spatial resolution. Thus, AFM offers the possibility to trace changes in the reorganization of the cytoskeleton in living cells. Impairments in the structure, organization, and functioning of two main cytoskeletal components, namely, actin filaments and microtubules, cause severe effects, leading to cell death. That is why these cytoskeletal components are targets for antitumor therapy. This review intends to describe the gathered knowledge on the capability of AFM to trace the alterations in the nanomechanical properties of living cells induced by the action of antitumor drugs that could translate into their effectiveness.Entities:
Keywords: antitumor drugs; atomic force microscopy; cell biomechanics; cell cytoskeleton; monitoring drug efficiency
Year: 2020 PMID: 33233645 PMCID: PMC7699791 DOI: 10.3390/ijms21228786
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(a) Illustration of the main elements constituting an atomic force microscope (AFM). (b) In the AFM-based elasticity measurements, a grid is placed over a central part of the cell. At each point, a so-called force curve is recorded (inset). (c) In nanomechanical analysis, the approach part of the calibration force curve (reference, curve acquired on a stiff, non-deformable surface) is subtracted from that measured on a cell. The obtained relation between the force and indentation is further used to calculate Young’s (elastic) modulus by applying Hertz contact mechanics with Sneddon modifications approximating the geometry of the probing tip. Typically, either a paraboloidal or a conical shape of the indenting AFM tip is considered. (d) The final Young’s modulus is frequently derived from a histogram by fitting Gauss or lognormal functions (exemplary results obtained for U138 glioma cells analyzed with Hertz–Sneddon mechanics, assuming a conical shape of the probing AFM tip).
Figure 2(a) A scheme showing the organization of three main cytoskeletal elements (actin and intermediate filaments, microtubules) inside the cell in relation to the cell membrane and nucleus (MTOC–a microtubule-organizing center). (b) Exemplary fluorescent images were collected for DU145 prostate cancer cells showing labeled actin filaments and microtubules.
Figure 3Nanomechanical properties of glioma U118 cells (a) before and (b) after the treatment with cytochalasin D (cyto D, 5 µg/mL, 10 min). Cytochalasin D induces a softening of the cells linked with reorganization (depolymerization) of the actin filaments. Insets: Images showing actin filaments stained fluorescently with phalloidin Alexa Fluor 488 dye.
Mechanical properties of cancerous cells measured by AFM, treated mainly with taxol.
| Drug | Cell Type | Dose | Elasticity Change ( | Reference |
|---|---|---|---|---|
| Paclitaxel | prostate cancer | 2 and 10 µM | Ren et al. 2015 [ | |
| Docetaxel | prostate cancer | 150 nM | Raudenska et al. [ | |
| Docetaxel | prostate cancer | 200 nM | Raudenska et al. [ | |
| Paclitaxel | melanoma | 24 nM | no change | Lin et al. [ |
| Paclitaxel | melanoma | 287 nM | Lin et al. [ | |
| Paclitaxel | melanoma | 20 nM | no change | Lin et al. [ |
| Paclitaxel | melanoma | 42 nM | Lin et al. [ | |
| Paclitaxel | endometrial cancer | 50 µM | Kim et al. [ | |
| Colchicine | hepatocellular | 0.1 µM | no change | Liu et al. [ |
| Colchicine | hepatocellular | 0.1 µM | Liu et al. [ |
Mechanical properties of the cancer cells treated with drugs that indirectly target the cytoskeleton; their effect manifests as changes in the cell’s biomechanics.
| Drug | Cell Type | Dose | Elasticity Change ( | Reference |
|---|---|---|---|---|
| Chitosan | non-malignant cell cancer of ureter (HCV29) | 0.05% | no effect | Lekka et al. [ |
| Chitosan | transitional cell carcinoma (T24) | 0.05% | Lekka et al. [ | |
| NHP-1 | prostate cancer | 5 µM | Gaspar et al. [ | |
| Disulfiram | prostate cancer | 1 and 2 µM | Ren et al. 2015 [ | |
| Tomatine | prostate cancer | 1 and 3 µM | Ren et al. 2015 [ | |
| BAY 11-7082 | prostate cancer | 2 and 5 µM | Ren et al. 2015 [ | |
| Vaproic acid | prostate cancer | 2 and 10 µM | Ren et al. 2015 [ | |
| 12-O-tetradecanoylphorbol-13-acetate | prostate cancer | 2 and 20 µM | Ren et al. 2015 [ | |
| Celebrex | prostate cancer | 2 and 10 µM | Ren et al. 2015 [ | |
| MK-2206 | prostate cancer | 2 and 10 µM | Ren et al. 2015 [ | |
| NMDA | neuroblastoma | 5 µM | Fang et al. [ | |
| NMDA | neuroblastoma | 200 µM | Fang et al. [ | |
| Cetuximab | lung cancer | 20 nM | Zhang et al. [ | |
| Resveratrol | breast cancer | 50 µM | Iturri et al. [ | |
| Resveratrol | breast cancer | 50 µM | no change | Iturri et al. [ |
| Resveratrol | breast cancer | 50 µM | Iturri et al. [ | |
| Resveratrol | breast cancer | 50 µM | Iturri et al. [ | |
| Cisplatin | prostate cancer | 24 µM | Raudenska et al. [ | |
| Cisplatin | prostate cancer | 93 µM | Raudenska et al. [ | |
| Disulfiram-Cu | nasopharyngeal carcinoma cells | 200 and 400 nM | Yang et al. [ | |
| Curcumin | liver carcinoma | 0.78 and 1.56 μg/mL | Olugbami et al. [ | |
| liver carcinoma | 25 and 50 μg/mL | Olugbami et al. [ | ||
| Dexamethasone | acute lymphoblastic leukemia (ALL) | 1 µM | Lam et al. [ | |
| Daunorubicin | acute lymphoblastic leukemia (ALL) | 1 µM | Lam et al. [ |